



BSHT Annual Scientific meeting 2022 | Wed 26 - Fri 28 January | P&J Live, Aberdeen

PROGRAMME

Wednesday 26 January

16:00	18:00	BSHT committee meeting	Bucksburn (Ground floor) Hilton Hotel
		ECR session - Career chats on the couch An informal opportunity to meet and network with other ECR's and hear informal career development talks. Organised and hosted by: Jo Mitchell and Claire Whyte <i>A light buffet will be provided</i>	
18:15	20:15	This is the first British Society of Haemostasis and Thrombosis early career researcher networking and career development event. This is an unmissable opportunity to build your thrombosis and haemostasis network and gain valuable career advice from postdoc to fellowship from experts in the field. Useful guide to 'preparing for your first postdoctoral position' <i>This will take you through getting your CV ready, preparing postdoc applications and getting ready for interviews.</i> Dr Timea Feller (University of Leeds) A valuable insight into 'planning, preparing for and applying for fellowships' Dr Julie Rayes (University of Birmingham) A useful guide to 'building successful collaborations' to help you learn how to expand your network and form links with other labs and researchers Professor Jon Gibbins (University of Reading) A very useful guide to 'Getting that clinical research fellowship' Dr Paraskevi Untiveros (Aberdeen Royal Infirmary) An insightful overview of 'the ECR pathway from PhD to fellowship' to provide advice and tips on how to get the best out of your years as an ECR Professor Mirela Delibegovic (University of Aberdeen)	Cask & Crema (Ground floor) Hilton Hotel
19:30	22:30	Faculty dinner	Stoneywood (Ground floor) Hilton Hotel

Thursday 27 January

08:30	10:20	Registration	1st floor landing
09:00	10:20	Refreshments Networking Exhibition	Conference Suite 1B/C
10:20	10:30	Welcome + Introduction Dr Nikki Mutch (BSHT President)	Conference Suite 1A
10:30	12:20	SESSION ONE: Plenary 1 and Oral Communications 1 <i>Co-chairs: Robert ARIENS & Rachel STAPLEY</i>	Conference Suite 1A
10:30	11:05	Plenary 1: Novel ligands for platelet glycoprotein receptors Steve WATSON (University of Birmingham) 5 mins Q&A	
		Oral Communications 1 <i>Co-chairs: Henry WATSON & Cédric DUVAL</i>	Conference Suite 1A
11:05	11:20	OC 1 Novel inhibitory GPVI antibodies block the GPVI ligand binding domain Eva Maria Soriano Jerez	
11:20	11:35	OC 2 Anti-GPVI Nanobody 2 disrupts Collagen and Atherosclerotic Plaque induced GPVI Signalling and prevents Receptor Clustering under Flow Natalie Jooss	
11:35	11:50	OC 3 A differential effect of CLEC-2 divalent ligands on human and mouse platelets Joanne Clark	
11:50	12:05	OC 4 Galectin-9 activates platelet ITAM receptors Glycoprotein VI and C-type Lectin-like Receptor 2 Zhaogong Zhi	
12:05	12:20	OC 5 The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity Christopher Smith	
12:20	12:45	BSHT AGM	
12:20	13:20	Lunch Networking Exhibition	Conference Suite 1B/C
13:20	15:10	SESSION TWO: Plenary 2 and Scientists in Training <i>Chair: Catherine BAGOT</i>	Conference Suite 1A
13:20	13:55	Plenary 2: Pathophysiology of trauma induced coagulopathy Nikki CURRY (Radcliffe Department of Medicine, University of Oxford) 5 mins Q&A	
		Scientists in Training <i>Co-Chairs: Nikki MUTCH & Fraser MACRAE</i>	
13:55	14:10	1 Fibrin Film and its Interactions with Red Blood Cells and Platelets Ghadir Alkarithi	
14:10	14:25	2 Neutrophils and NETs Produce Clots with Different Types of Fibrin Fibers Yu Shi	

14:25	14:40	3 HSP47 regulates collagen structure and synthesis by megakaryocytes Gemma Little	
14:40	14:55	4 Shear-induced platelet reactivity in native blood assessed at the point-of-care correlates with thrombin generation in patients with myocardial infarction Rahim Kanji	
14:55	15:10	5 Plasminogen Activator Inhibitor-1 and its cofactor vitronectin induce a hypofibrinolytic state in COVID-19 disease which correlates with disease severity Megan Simpson	
15:10	15:40	<i>Refreshments Networking Exhibition</i>	Conference Suite 1B/C
15:40	17:45	SESSION THREE: Plenary 3 and Emerging Fellows <i>Chair: Nikki CURRY</i>	Conference Suite 1A
15:40	16:15	Plenary 3: COVID-19 and clots: current uncertainty & controversy Beverley HUNT (Guy's & St Thomas's, London) 5 mins Q&A	
		Emerging Fellows <i>Co-chairs: Isabelle SALLES-CRAWLEY & Claire WHYTE</i>	Conference Suite 1A
16:15	16:40	Danger-associated molecular patterns S100 A8/A9 and heme as novel targets in thrombo-inflammation <i>Novel triggers of thrombo-inflammation resistant to anti-platelet drugs</i> Julie RAYES (University of Birmingham) 5 mins Q&A	
16:40	17:05	Pathophysiology underlying the increased risk of thrombosis in overweight and obese pregnant women The results of a prospective, longitudinal study aiming to characterize the prothrombotic phenotype of obesity during pregnancy using thrombin generation. Susan MCNEILL (University of Glasgow) 5 mins Q&A	
17:05	17:30	Fibrin(ogen), a double-edged sword in thrombosis and wound healing <i>During this talk I will be discussing my research on the positive and negative influences of fibrin(ogen) in thrombosis and wound healing.</i> Fraser MACRAE (University of Leeds) 5 mins Q&A	
17:30	17:55	Non-invasive in vivo coronary artery thrombus imaging Evangelos TZOLOS (University of Edinburgh) 5 mins Q&A	
17:55	18:45	Comfort break	
18:45	19:45	Poster session + Drinks reception	The View
	P-01	Characterisation of 17 Novel Von Willebrand Factor Missense Mutations Michael Appiah	
	P-02	Bleeding and thrombotic complications and their impact on mortality in patients supported with left ventricular assist device for cardiogenic shock Ingrid Bekono-Nessah	
	P-03	Long term outcomes of the use of statins for angiodyspasia in Von Willebrand disease Christina Crossette-Thambiah	
	P-04	Tranexamic acid has a direct impact on the structure of the fibrin network Louis de Bernard	
	P-05	Prior oral anticoagulation therapy and clinical outcomes in stroke patients with atrial fibrillation in Scotland: A national database study Victor Ezenwajaku	
	P-06	Using CRISPR/Cas9 to investigate the structure/function relationship of PLCy2 in platelets Safa Gayes	
	P-07	Impact of aspirin on bleeding and thrombosis in on-pump and off-pump coronary artery bypass graft Christopher Little	
	P-08	Cost effective flow assays – using 3D printing for cheap and cheerful microfluidics Tom McKinnon	
	P-09	Severe COVID-19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis Tom McKinnon	
	P-10	Analysis of Von Willebrands Disease causing mutations located in the D4 and C-domains Golzar (Golly) Mobayen	
	P-11	Splenectomy in refractory chronic immune thrombocytopenic purpura with equal sequestration of platelets in both liver and spleen on Indium labelled platelet survival study Meheroon Nahar	
	P-12	Is there a role for Anti-Xa monitoring to ensure safe DOAC efficacy in clinical practice? Ramandeep Puni	
	P-13	UK NEQAS (Blood Coagulation) Genetics of Heritable Bleeding and Thrombotic disorders programme - a review of External Quality Assessment (EQA) Scheme exercises 2021 Christopher Reilly-Stitt	
	P-14	Measurement of fibrinogen using two concentrations of Thrombin with patients receiving Argatroban therapy or normal plasma spiked with Argatroban: a review of UK NEQAS (Blood Coagulation) External Quality Assessment Scheme exercises 2021 Christopher Reilly-Stitt	
	P-15	Monitoring Emeticumab-data from a World Federation of Haemophilia International External Quality Assessment Scheme exercise Christopher Reilly-Stitt	
	P-16	Zinc dietary intake in humans regulates zinc platelet pool and impacts on haemostatic parameters Um-May Sumya	
	P-17	Changing haematocrit in patients with autoimmune haemolytic anaemia affects clot formation and resistance to fibrinolysis Paraskevi Untiveros	
19:45	22:30	<i>Conference dinner - Burns Supper</i>	The View Area Conference Suite 2A

Friday 28 January

08:00	08:30	<i>Registration Refreshments Networking Exhibition</i>	Conference Suite 1B/C
08:30	10:10	SESSION FOUR: Plenary 4 and Oral Communications 2	Conference Suite 1A

		<i>Chairs: Steve WATSON</i>		
08:30	09:05	Plenary 4: Vaccine-induced immune thrombocytopenia and thrombosis: One year on, what have we learnt? <i>A whistle stop tour of our current understanding of the pathophysiology, diagnosis and management of vaccine-induced immune thrombocytopenia and thrombosis (VITT)</i> Catherine BAGOT (Department of Haematology, Glasgow Royal Infirmary)	5 mins Q&A	
09:05	09:10	Transfer to parallel session		
		Oral Communications 2		Clinical Education Session
		<i>Conference Suite 1A</i>		<i>Meeting Room 4</i>
		<i>Co-Chairs: Helen PHILIPPOU + Tom McKINNON</i>		<i>Organised and chaired by: Henry WATSON</i>
09:10	09:25	OC 6 Impaired fibrin a-chain cross-linking in a new genetically modified murine model Cédric Duval	09:10 - 09:40	Issues in the emergency management of ischaemic stroke <i>When to thrombolysise and/or refer for thrombectomy?</i> Mary Joan MCLEOD (University of Aberdeen)
09:25	09:40	OC 7 Rare missense variants in Tropomyosin-4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects and excessive bleeding Rachel Stapley		5 mins Q&A
09:40	09:55	OC 8 A simple in vitro model of thrombosis to assess the impact of endothelial dysfunction on antiplatelet efficacy Sarah Jones	09:40 - 10:05	Cerebral Venous Sinus Thrombosis: A pre-VITT era case and clinical observations in a cohort of patients with CVST Thura WIN HTUT (Aberdeen Royal Infirmary)
09:55	10:10	OC 9 Anti-Thrombotic Effects of the Proteasome Inhibitor Carfilzomib on the Endothelium Ahmed HJazi		5 mins Q&A
10:10	10:40	<i>Refreshments Networking Exhibition- (Conference Suite 1B/C)</i>	10:05 - 10:35	Pregnancy complications of Sickle Cell Disease Beverley ROBERTSON (Aberdeen Royal Infirmary)
10:40	11:40	SESSION FIVE: Oral Communications 3		Clinical Education Session
		<i>Conference Suite 1A</i>		<i>Meeting Room 4</i>
		<i>Co-chairs: Craig HUGHES & Gael MORROW</i>		
10:40	10:55	OC 10 Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure by elevating PAI-1; results from a sub-study of the FEISTY trial Gael B Morrow	10:35 - 11:00	Catastrophic Antiphospholipid syndrome (CAPS) Wail ABDELRAHMAN (Aberdeen Royal Infirmary)
10:55	11:10	OC 11 Fatty acids modulate zinc-dependent coagulation through albumin binding in type 2 diabetes Alan J. Stewart	11:00 - 11:30	An approach to the diagnosis of suspected heritable platelet disorders Current approaches and prospects for diagnosis of heritable platelet disorders in the omics era. Andrew PAGE (Royal Infirmary of Edinburgh)
11:10	11:25	OC 12 Platelet factor XIII-A regulates platelet function and promotes clot retraction intracellularly and functions extracellularly by enhancing fibrinolytic stability of clots via procoagulant platelet formation Joanne Mitchell		5 mins Q&A
11:25	11:40	OC 13 BTK inhibitors, platelet inhibition and bleeding risk: How low can you go? Alex Bye		
			11:30 - 11:40	Comfort break - rejoin main session
11:40	13:00	SESSION SIX: Summer students + Plenary five		Conference Suite 1A
		<i>Co-chairs: Neil MORGAN & Joanne MITCHELL</i>		
11:40	11:45	1 Developing a model of trauma induced coagulopathy using a functional plasmin generation assay Louis DE BERNARD (University of Oxford and University of Aberdeen)		
11:45	11:50	2 Investigating the role of Gasdermin D in platelet function and thrombosis Amar BHAGANIA (University of Birmingham)		
11:50	11:55	3 Investigating Sex-Specific Differences in the Antithrombotic Capacity of Endothelial Cells Eima KARIM (Manchester Metropolitan University)		
11:55	12:30	Plenary 5 Thrombus on a chip – modelling the human vasculature Matthew HARPER (University of Cambridge)	5 mins Q&A	
12:30	13:30	<i>Lunch Networking Exhibition</i>		Conference Suite 1B/C
13:30	15:20	SESSION SEVEN: Plenary six and Oral Communications 4		Conference Suite 1A
		<i>Co-Chairs: Mike LAFFAN</i>		
13:30	14:05	Plenary 6 The contact pathway as a target for antithrombotic drugs <i>This presentation will provide an oversight of contact pathway inhibitors in development as next generation anticoagulants.</i> Helen PHILIPPOU (University of Leeds)	5 mins Q&A	
		Oral Communications 4		Conference Suite 1A
		<i>Co-Chairs: Jon GIBBINS + Julie RAYES</i>		
14:05	14:20	OC 14 The efficacy of fibrinogen concentrates in restoring clot integrity and stability against lysis Claire S Whyte		
14:20	14:35	OC 15 A pilot, open-label, phase II clinical trial of nebulised recombinant tissue-plasminogen activator in patients with COVID-19 acute respiratory distress syndrome: the PACA trial Pratima Chowdary		
14:35	14:50	OC 16 7 month follow up of cerebral venous sinus thrombosis following ChAdOx1 nCov-19 Vaccination: a single centre experience Christina Crossette-Thambiah		
14:50	15:05	OC 17 Metabolic reprogramming is essential for myeloid cell-dependent haemostatic activity Aisling M Rehill		

15:05	15:20	OC 18 Anti-PF ₄ IgG levels in patients with VITT remain high at 6 months following vaccination Samantha Montague
15:20		Closing remarks and meeting close Nikki MUTCH
15:30		Attendee departure
